Global

Oncology Experts

Miguel Martín

professor
Valencian Institute of Oncology
Universitat de Valencia
Spain

Biography

Miguel Martín is working in Miguel Martín, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense; Carlos Jara, Fundación Hospitalaria de Alcorcón; Noelia Martínez-Jáñez, Hospital Universitario Ramón y Cajal; César Mendiola Fernández, Hospital Universitario; Ana Isabel Ballesteros, Hospital de la Princesa; Maribel Casas, María del Carmen Cámara, and Eva Carrasco, GEICAM Headquarters, Madrid; Amparo Ruiz Simón, Instituto Valenciano de Oncología; Ana Santaballa, Hospital Universitario La Fe; Ana Lluch, Hospital Clínico Universitario de Valencia-INCLIVA-Universidad de Valencia, Valencia; Manuel Ruiz Borrego, Hospital Universitario Virgen del Rocío, Sevilla; Nuria Ribelles, Hospital Universitario Virgen de la Victoria IBIMA, Málaga; Álvaro Rodríguez-Lescure, Hospital General de Elche; Encarna Adrover, Hospital Clínico Universitario de Alicante, Alicante; Montserrat Muñoz-Mateu, Hospital Clinic i Provincial; Sonia González, Hospital Mutua de Terrassa; Mireia Margelí Vila, Hospital Universitario Germans Trias i Pujol; Agustí Barnadas, Universitat Autònoma de Barcelona, Barcelona; Manuel Ramos, Centro Oncológico de Galicia; Lourdes Calvo, Complejo Hospitalario Universitario A Coruña, A Coruã; Sonia Del Barco Berron, Instituto Catalán de Oncología, Girona; César A. Rodríguez, Hospital Universitario de Salamanca, Salamanca, Spain; Eduardo Martínez de Dueñas, Hospital Provincial de Castellón, Castellón; Raquel Andrés, Hospital Universitario Lozano Blesa, Zaragoza; Arrate Plazaola, Onkologikoa, San Sebastián; Juan de la Haba-Rodríguez, Universidad de Córdoba, Córdoba; Jose Manuel López-Vega, Hospital Universitario Marqués de Valdecilla, Santander; Pedro Sánchez-Rovira, Complejo Hospitalario de Jaén, Jaén; and José M. Baena-Cañada, Hospital Universitario Puerta del Mar, Cádiz, Spain.

Research Interest

Oncology

Publications

  • Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.

Global Experts from Spain

Global Experts in Subject

Share This Profile
Recent Expert Updates
  • Matthew L Stone
    Matthew L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.   Matthew
    Dr. Matthew
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  L Stone Matthew
    Dr. L Stone Matthew
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  L Stone
    Dr. L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr. Matthew L Stone
    Dr. Matthew L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  R Sameh
    Dr. R Sameh
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   R Ismail,
    Dr. R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Sameh R Ismail,
    Sameh R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   Sameh R Ismail,
    Dr. Sameh R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   William
    Dr. William
    pediatrics
    Maimonides Medical Center
    United States of America